Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Emergent BioSolutions issued task order for COVID-19 vaccine development » 06:41
06/01/20
06/01
06:41
06/01/20
06:41
EBS

Emergent BioSolutions

$83.55 /

+1.65 (+2.01%)

Emergent BioSolutions…

Emergent BioSolutions announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health & Human Services, to deploy its contract development and manufacturing capacities, capabilities, and expertise to support the U.S. government's efforts to accelerate delivery of COVID-19 vaccines. This task order, valued at approximately $628M, is being issued under the company's 2012 contract with BARDA that established Emergent's Baltimore Bayview facility as a Center for Innovation in Advanced Development and Manufacturing for pandemic preparedness, and expands the partnership to include investments in Emergent's Baltimore Camden and Rockville facilities, creating a U.S.-based manufacturing supply chain for pharmaceutical and biotechnology innovators of COVID-19 vaccine candidates. Under the task order, Emergent will deploy its molecule-to-market CDMO offering, committing manufacturing capacity, valued at approximately $542.7M, for production of COVID-19 vaccine candidates through 2021. This award secures, on behalf of leading COVID-19 vaccine innovators that are supported by the U.S. government, capacity for drug substance manufacturing at the company's Baltimore Bayview facility and for drug product manufacturing at the Baltimore Camden and Rockville locations. The task order also includes an investment of approximately $85.5M for the rapid expansion of Emergent's viral and non-viral CDMO drug product fill/finish capacity at the Baltimore Camden and Rockville facilities.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$83.55 /

+1.65 (+2.01%)

EBS Emergent BioSolutions
$83.55 /

+1.65 (+2.01%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
EBS Emergent BioSolutions
$83.55 /

+1.65 (+2.01%)

EBS Emergent BioSolutions
$83.55 /

+1.65 (+2.01%)

Over a week ago
Hot Stocks
Emergent BioSolutions CEO: We're here to support vaccine candidates » 18:44
05/04/20
05/04
18:44
05/04/20
18:44
EBS

Emergent BioSolutions

$79.41 /

+0.81 (+1.03%)

In an interview on…

In an interview on CNBC's Mad Money, Robert Kramer said Emergent BioSolutions has a history of focusing on public health threats. "We've built a model around helping the public respond to threats," he said. Kramer noted EBS could potentially make hundreds of millions of doses of a COVID-19 vaccine available to the public. He added that EBS is doing everything it can to make sure a vaccine is available and shorten the development process.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$79.41 /

+0.81 (+1.03%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
Over a month ago
Earnings
Emergent BioSolutions reports Q1 EPS (1c), consensus 1c » 16:27
04/30/20
04/30
16:27
04/30/20
16:27
EBS

Emergent BioSolutions

$74.48 /

+0.61 (+0.83%)

Reports Q1 revenue…

Reports Q1 revenue $192.5M, consensus $199.47M. "Emergent is uniquely positioned to respond to the unprecedented challenges of the COVID-19 pandemic," said Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions. "We are deploying our decades of experience in vaccines and therapeutics development and manufacturing, our well-established platform technologies, and our significant development and manufacturing capabilities. Our goal is to create multiple innovative solutions to deliver on our commitments to our customers and patients, while continuing to safeguard our employees."

ShowHide Related Items >><<
EBS Emergent BioSolutions
$74.48 /

+0.61 (+0.83%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
On The Fly
Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades » 13:41
04/27/20
04/27
13:41
04/27/20
13:41
MYOV

Myovant Sciences

$12.12 /

-0.02 (-0.16%)

, AIMT

Aimmune

$18.50 /

+0.89 (+5.05%)

, AXDX

Accelerate Diagnostics

$10.83 /

+0.6 (+5.87%)

, CFG

Citizens Financial

$22.20 /

+1.61 (+7.82%)

, VOXX

VOXX

$5.12 /

+0.14 (+2.81%)

, KMB

Kimberly-Clark

$140.61 /

-1.075 (-0.76%)

, PGNY

Progyny

$21.36 /

+0.75 (+3.64%)

, EBS

Emergent BioSolutions

$77.32 /

+4.12 (+5.63%)

, ABT

Abbott

$94.71 /

+0.665 (+0.71%)

, ACAD

Acadia

$52.38 /

+1.54 (+3.03%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
MYOV Myovant Sciences
$12.12 /

-0.02 (-0.16%)

02/03/20 Citi
Myovant Sciences resumed with a Neutral from Buy at Citi
11/19/19 Goldman Sachs
Myovant Sciences price target raised to $20 from $18 at Goldman Sachs
11/19/19 JMP Securities
JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data
08/28/19
Fly Intel: Top five analyst initiations
AIMT Aimmune
$18.50 /

+0.89 (+5.05%)

04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
03/23/20 Cantor Fitzgerald
Aimmune price target lowered to $32 from $64 at Cantor Fitzgerald
03/18/20 JMP Securities
Aimmune downgraded to Market Perform from Outperform at JMP Securities
AXDX Accelerate Diagnostics
$10.83 /

+0.6 (+5.87%)

01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
09/27/19 JPMorgan
Accelerate Diagnostics downgraded to Underweight from Neutral at JPMorgan
08/09/19 Piper Sandler
Accelerate Diagnostics price target lowered to $19 from $22 at Piper Jaffray
CFG Citizens Financial
$22.20 /

+1.61 (+7.82%)

04/20/20 Morgan Stanley
Amazon removed from Fresh Money Buy List at Morgan Stanley
04/14/20 Compass Point
Citizens Financial initiated with a Neutral at Compass Point
01/06/20 Barclays
Citizens Financial upgraded to Overweight from Equal Weight at Barclays
12/16/19 Citi
Citizens Financial upgraded to Neutral from Sell at Citi
VOXX VOXX
$5.12 /

+0.14 (+2.81%)

KMB Kimberly-Clark
$140.61 /

-1.075 (-0.76%)

03/30/20 Jefferies
Kimberly-Clark upgraded to Buy from Hold at Jefferies
02/25/20 Evercore ISI
Reynolds Consumer Products initiated with an Outperform at Evercore ISI
10/23/19 Deutsche Bank
Deutsche Bank upgrades Kimberly-Clark to Hold on expectations reset
10/22/19 Deutsche Bank
Kimberly-Clark upgraded to Hold from Sell at Deutsche Bank
PGNY Progyny
$21.36 /

+0.75 (+3.64%)

04/09/20 JPMorgan
Progyny should see 'very strong recovery' in 2021, says JPMorgan
11/19/19 JPMorgan
Progyny initiated with an Overweight at JPMorgan
11/19/19 Citi
Progyny initiated with a Buy at Citi
11/19/19 SVB Leerink
Progyny initiated with an Outperform at SVB Leerink
EBS Emergent BioSolutions
$77.32 /

+4.12 (+5.63%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
ABT Abbott
$94.71 /

+0.665 (+0.71%)

04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/17/20 Raymond James
Abbott price target raised to $102 from $92 at Raymond James
04/17/20 Credit Suisse
Abbott price target raised to $106 from $95 at Credit Suisse
ACAD Acadia
$52.38 /

+1.54 (+3.03%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
On The Fly
Fly Intel: After-Hours Movers » 19:04
04/23/20
04/23
19:04
04/23/20
19:04
WWE

WWE

$39.05 /

-0.39 (-0.99%)

, CYBE

Cyberoptics

$21.71 /

+1.11 (+5.39%)

, TPH

TRI Pointe

$9.60 /

+0.01 (+0.10%)

, VCRA

Vocera

$18.00 /

+0.015 (+0.08%)

, EW

Edwards Lifesciences

$220.78 /

+4.585 (+2.12%)

, MMSI

Merit Medical

$37.73 /

+0.82 (+2.22%)

, RHI

Robert Half

$43.77 /

+2.36 (+5.70%)

, EBS

Emergent BioSolutions

$66.73 /

+0.14 (+0.21%)

, OZK

Bank OZK

$17.65 /

+0.29 (+1.67%)

, LLNW

Limelight Networks

$5.81 /

-0.19 (-3.17%)

, INTC

Intel

$59.09 /

-1.02 (-1.70%)

, EHTH

eHealth

$126.77 /

+7.58 (+6.36%)

, COF

Capital One

$52.70 /

+1.17 (+2.27%)

, ETFC

E-Trade

$38.27 /

-0.34 (-0.88%)

, SKX

Skechers

$24.74 /

-0.3 (-1.20%)

, BA

Boeing

$137.61 /

+2.71 (+2.01%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WWE WWE
$39.05 /

-0.39 (-0.99%)

04/20/20 Wells Fargo
WWE price target lowered to $30 from $36 at Wells Fargo
04/17/20
Fly Intel: Top five analyst upgrades
04/17/20 Benchmark
WWE upgraded to Buy on better visibility at Benchmark
04/17/20 Benchmark
WWE upgraded to Buy from Hold at Benchmark
CYBE Cyberoptics
$21.71 /

+1.11 (+5.39%)

02/20/20 Craig-Hallum
Cyberoptics price target raised to $29 from $20 at Craig-Hallum
02/20/20 Lake Street
Cyberoptics price target raised to $27 from $20 at Lake Street
10/24/19 Lake Street
Cyberoptics price target raised to $20 from $18 at Lake Street
07/03/19 Lake Street
Cyberoptics price target lowered to $18 from $25 at Lake Street
TPH TRI Pointe
$9.60 /

+0.01 (+0.10%)

04/02/20 Evercore ISI
TRI Pointe upgraded to In Line from Underperform at Evercore ISI
03/17/20 B. Riley FBR
B. Riley FBR downgrades seven Industrials on broadening COVID-19 impact
03/17/20 B. Riley FBR
TRI Pointe downgraded to Neutral from Buy at B. Riley FBR
11/01/19 JMP Securities
TRI Pointe downgraded to Market Perform at JMP Securities on valuation
VCRA Vocera
$18.00 /

+0.015 (+0.08%)

04/13/20 SVB Leerink
Vocera initiated with an Underperform at SVB Leerink
03/02/20 Guggenheim
Vocera price target raised to $29 after management meetings at Guggenheim
03/02/20 RBC Capital
Vocera price target raised to $26 from $22 at RBC Capital
02/18/20 Baird
Vocera can get back above $30, Baird says in upgrade to Outperform
EW Edwards Lifesciences
$220.78 /

+4.585 (+2.12%)

04/22/20 Deutsche Bank
Edwards Lifesciences price target lowered to $225 from $245 at Deutsche Bank
04/20/20 Cowen
Edwards Lifesciences price target lowered to $250 from $275 at Cowen
04/17/20 SVB Leerink
Edwards Lifesciences upgraded to Outperform from Market Perform at SVB Leerink
04/17/20 SVB Leerink
Edwards Lifesciences upgraded to Outperform from Market Perform at SVB Leerink
MMSI Merit Medical
$37.73 /

+0.82 (+2.22%)

04/20/20 Wells Fargo
Wells Fargo sees COVID-19 collection kits as incremental opportunity for Merit
04/14/20 Piper Sandler
J&J provided 'valuable' information on outlook for medtech, says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
02/25/20 Barrington
Barrington downgrades Merit Medical to Market Perform on coronavirus risk
RHI Robert Half
$43.77 /

+2.36 (+5.70%)

04/20/20 BMO Capital
Robert Half price target lowered to $45 from $61 at BMO Capital
04/15/20 CL King
Robert Half price target lowered to $60 from $70 at CL King
04/06/20 Goldman Sachs
Goldman cuts staffing estimates, says buy Korn/Ferry, sell Robert Half
03/05/20 Northcoast
Robert Half risk/reward more balanced at current levels, says Northcoast
EBS Emergent BioSolutions
$66.73 /

+0.14 (+0.21%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
OZK Bank OZK
$17.65 /

+0.29 (+1.67%)

03/06/20 SunTrust
SunTrust cuts price targets on Banks amid lower interest rate environment
01/10/20 Piper Sandler
Bank OZK upgraded to Overweight from Neutral at Piper Sandler
01/02/20 SunTrust
SunTrust raises price targets on select regional banks on improved margins
LLNW Limelight Networks
$5.81 /

-0.19 (-3.17%)

04/21/20 Cowen
Limelight Networks upside results and guidance seen, says Cowen
04/21/20 B. Riley FBR
Limelight Networks price target raised to $7.50 from $6.50 at B. Riley FBR
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Northland
Limelight Networks initiated with an Outperform at Northland
INTC Intel
$59.09 /

-1.02 (-1.70%)

04/23/20 Raymond James
Apple using own Mac chips a 'potential black eye' for Intel, says Raymond James
04/22/20 Jefferies
Intel price target raised to $62 from $53 at Jefferies
04/16/20 Northland
Intel Q1 'as good as it gets' for 2020, says Northland
04/14/20 Wells Fargo
AMD deepening Intel competitive push in new EPYC server CPUs, says Wells Fargo
EHTH eHealth
$126.77 /

+7.58 (+6.36%)

04/16/20 Barclays
eHealth initiated with an Overweight at Barclays
04/08/20 Cantor Fitzgerald
eHealth selloff on short report overdone, says Cantor Fitzgerald
04/08/20 RBC Capital
Muddy Waters short report on eHealth 'nothing new,' says RBC
04/08/20 SunTrust
SunTrust 'comfortable' with eHealth accounting, says buy on selloff
COF Capital One
$52.70 /

+1.17 (+2.27%)

04/13/20 Deutsche Bank
Capital One price target lowered to $86 from $110 at Deutsche Bank
04/08/20 Wells Fargo
Capital One price target lowered to $82 from $115 at Wells Fargo
03/30/20 Keefe Bruyette
Capital One CFTC reporting relief concerns overdone, says Keefe Bruyette
03/26/20 Oppenheimer
Capital One upgraded to Outperform at Oppenheimer
ETFC E-Trade
$38.27 /

-0.34 (-0.88%)

04/06/20 Wells Fargo
Broker sector has plenty of fundamental challenges, says Wells Fargo
03/06/20 Wells Fargo
Wells Fargo cuts price targets for brokers on lower interest rate environment
02/27/20 UBS
E-Trade downgraded to Neutral from Buy at UBS
02/26/20 Raymond James
E-Trade downgraded at Raymond James following sale announcement
SKX Skechers
$24.74 /

-0.3 (-1.20%)

03/30/20 Wells Fargo
Skechers upgraded to Overweight from Equal Weight at Wells Fargo
03/19/20 Deutsche Bank
Skechers price target lowered to $28 from $51 at Deutsche Bank
12/18/19 Deutsche Bank
Deutsche Bank starts 'underappreciated' Skechers with Buy, $49 target
12/17/19 Deutsche Bank
Skechers initiated with a Buy at Deutsche Bank
BA Boeing
$137.61 /

+2.71 (+2.01%)

04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Citi
Citi downgrades Boeing to Neutral on 'collapsed' aerospace story
04/20/20 Citi
Boeing downgraded to Neutral from Buy at Citi
04/13/20 BofA
BofA downgrades Spirit AeroSystems to Underperform, slashes price target to $25
Hot Stocks
Emergent to be U.S. manufacturing partner for J&J's COVID-19 vaccine candidate » 18:54
04/23/20
04/23
18:54
04/23/20
18:54
EBS

Emergent BioSolutions

$66.73 /

+0.14 (+0.21%)

, JNJ

Johnson & Johnson

$155.70 /

+2.79 (+1.82%)

Emergent BioSolutions…

Emergent BioSolutions Inc. (EBS) announced an agreement whereby Emergent will deploy its contract development and manufacturing services to support the manufacturing of Johnson & Johnson's (JNJ) lead vaccine candidate for COVID-19 that leverages the AdVac and PER.C6 technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson. Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions, stated, "When mission-driven organizations combine talents and capabilities, potential solutions to serious issues like COVID-19 become more within reach to benefit patients. We are proud of our collaboration with Johnson & Johnson and are equally committed to our longstanding relationship with the U.S. government. At a time like this, we all need to be working together to achieve maximum results for public health. Emergent is committed to our mission - to protect and enhance life - by advancing our own therapies and helping partner companies advance their programs as well." Under the agreement, valued at approximately $135 million, Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering, supported by investments from Johnson & Johnson beginning in 2020, and will reserve certain large-scale manufacturing capacity to pave the way for commercial manufacturing of Janssen's adenovirus-based COVID-19 vaccine beginning in 2021. To support Johnson & Johnson's goal of supplying one billion doses of a COVID-19 vaccine, a long-term commercial manufacturing agreement is under negotiation for large-scale drug substance manufacturing anticipated to begin in 2021. Large-scale manufacturing of drug substance for Johnson & Johnson's vaccine candidate will be done at Emergent's Baltimore Bayview facility, a Center for Innovation in Advanced Development and Manufacturing (CIADM) designed for rapid manufacturing of vaccines and treatments in large quantities during public health emergencies. Emergent's CIADM is a result of a public-private partnership with the U.S. Department of Health and Human Services (HHS).

ShowHide Related Items >><<
EBS Emergent BioSolutions
$66.73 /

+0.14 (+0.21%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
JNJ Johnson & Johnson
$155.70 /

+2.79 (+1.82%)

04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 BofA
Johnson & Johnson upgraded to Buy on defensiveness at BofA
04/22/20 BofA
Johnson & Johnson upgraded to Buy from Neutral at BofA
04/15/20 DA Davidson
Prestige Consumer price target raised to $47 from $43 at DA Davidson
Hot Stocks
Emergent BioSolutions appoints Karen Smith as CMO » 16:58
04/21/20
04/21
16:58
04/21/20
16:58
EBS

Emergent BioSolutions

$66.95 /

-3.1 (-4.43%)

, JAZZ

Jazz Pharmaceuticals

$103.30 /

-5.58 (-5.12%)

Emergent BioSolutions…

Emergent BioSolutions (EBS) announced the appointment of Karen Smith as CMO with responsibility for leading and further establishing Emergent's global integrated capability in clinical development, medical affairs and regulatory affairs. Smith and her teams will work in partnership with the business units to advance the company's portfolio of products in development. She will be a member of the executive management team reporting to the president and CEO. Smith has previously served as CMO for Jazz Pharmaceuticals (JAZZ) and has held senior executive positions at various other pharmaceutical and biotechnology companies.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$66.95 /

-3.1 (-4.43%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
JAZZ Jazz Pharmaceuticals
$103.30 /

-5.58 (-5.12%)

04/06/20
Fly Intel: Top five analyst initiations
04/06/20 Jefferies
Jazz Pharmaceuticals initiated with a Buy at Jefferies
03/30/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $147 from $164 at RBC Capital
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
Hot Stocks
Emergent BioSolutions Partners with U.S. to expedite COVID-19 therapy » 16:15
04/02/20
04/02
16:15
04/02/20
16:15
EBS

Emergent BioSolutions

$57.20 /

+3.11 (+5.75%)

Emergent BioSolutions…

Emergent BioSolutions announced that it has entered into a formal partnership with the U.S. government to expedite development of a plasma-derived therapy for patients with coronavirus disease 2019 . Emergent has received $14.5 million from the Biomedical Advanced Research and Development Authority , part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, in support of its COVID-HIG program, one of two hyperimmune development programs announced by Emergent in March. COVID-HIG is a candidate human hyperimmune product being developed as a potential treatment for COVID-19 in severe hospitalized patients and high-risk, acute symptomatic patients to prevent progression to severe symptoms. COVID-HIG will be manufactured using plasma donations from people who have recovered from COVID-19 with antibodies to SARS-CoV-2.Emergent and the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health, have agreed to incorporate the company's COVID-HIG product candidate into one of NIAID's clinical studies for assessment of treatments for COVID-19 once clinical material is available, and the study begins. Emergent has already initiated plasma screening and collection of human plasma with antibodies to SARS-CoV-2 that will be further purified and concentrated through manufacturing of COVID-HIG.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$57.20 /

+3.11 (+5.75%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:57
04/01/20
04/01
12:57
04/01/20
12:57
GM

General Motors

$19.04 /

-1.73 (-8.33%)

, FCAU

Fiat Chrysler

$6.84 /

-0.355 (-4.94%)

, TMUS

T-Mobile

$83.92 /

+0.01 (+0.01%)

, S

Sprint

$8.61 /

+ (+0.00%)

, HPQ

HP Inc.

$15.52 /

-1.86 (-10.70%)

, XRX

Xerox

$17.70 /

-1.18 (-6.25%)

, KGC

Kinross Gold

$4.26 /

+0.275 (+6.91%)

, NVAX

Novavax

$13.80 /

+0.27 (+2.00%)

, ARNC

Arconic

$6.00 /

+ (+0.00%)

, CPRI

Capri Holdings

$9.03 /

-1.76 (-16.31%)

, WLL

Whiting Petroleum

$0.38 /

-0.2933 (-43.87%)

, EBS

Emergent BioSolutions

$54.04 /

-3.78 (-6.54%)

Stocks are starting off…

Open Full Text

ShowHide Related Items >><<
GM General Motors
$19.04 /

-1.73 (-8.33%)

03/24/20 Morgan Stanley
Morgan Stanley upgrades Auto industry rating to In-Line from Cautious
03/24/20 Citi
General Motors price target lowered to $53 from $68 at Citi
03/24/20 UBS
Tesla and BMW upgraded, Ford downgraded at UBS
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
FCAU Fiat Chrysler
$6.84 /

-0.355 (-4.94%)

12/18/19 Evercore ISI
Evercore ISI upgrades Fiat Chrysler to Outperform after Peugeot deal formalized
12/18/19 Evercore ISI
Fiat Chrysler upgraded to Outperform from In Line at Evercore ISI
TMUS T-Mobile
$83.92 /

+0.01 (+0.01%)

03/23/20 BofA
T-Mobile resumed with a Buy at BofA
03/09/20 Barclays
T-Mobile price target raised to $94 from $88 at Barclays
03/09/20 Wells Fargo
T-Mobile price target raised to $110 from $98 at Wells Fargo
03/06/20 Bernstein
Dish upgraded to Market Perform from Underperform at Bernstein
S Sprint
$8.61 /

+ (+0.00%)

03/02/20 BofA
SBA Communications upgraded to Buy from Neutral at BofA
HPQ HP Inc.
$15.52 /

-1.86 (-10.70%)

04/01/20 JPMorgan
Xerox bid withdrawal mild positive for HP holders, says JPMorgan
03/31/20 Argus
HP Inc. upgraded to Buy from Hold at Argus
03/31/20 Argus
HP Inc. upgraded to Buy from Hold at Argus
03/19/20 Loop Capital
HP Inc. price target lowered to $20 from $28 at Loop Capital
XRX Xerox
$17.70 /

-1.18 (-6.25%)

03/12/20 JPMorgan
JPMorgan upgrades to HP to Overweight, says buy ahead of catalysts
02/25/20 Morgan Stanley
HP Inc. price target raised to $24 from $21 at Morgan Stanley
KGC Kinross Gold
$4.26 /

+0.275 (+6.91%)

03/11/20 BMO Capital
BMO updates Kinross Gold estimates after Paracatu technical report
01/23/20
Fly Intel: Top analyst initiations
01/23/20 Credit Suisse
Kinross Gold reinstated with a Neutral at Credit Suisse
12/04/19 RBC Capital
Kinross Gold assumed with a Sector Perform at RBC Capital
NVAX Novavax
$13.80 /

+0.27 (+2.00%)

03/27/20 B. Riley FBR
Novavax price target raised to $20 from $15 at B. Riley FBR
03/25/20 Cantor Fitzgerald
Novavax price target raised to $23 from $16 at Cantor Fitzgerald
03/25/20 H.C. Wainwright
Novavax price target raised to $24 from $17 at H.C. Wainwright
03/24/20 Ladenburg
Novavax price target raised to $24 from $16 at Ladenburg
ARNC Arconic
$6.00 /

+ (+0.00%)

04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
02/18/20 Argus
Arconic upgraded to Buy from Hold at Argus
02/18/20 Argus
Arconic upgraded to Buy from Hold at Argus
CPRI Capri Holdings
$9.03 /

-1.76 (-16.31%)

03/30/20 Wells Fargo
Capri Holdings downgraded to Equal Weight from Overweight at Wells Fargo
03/19/20 Morgan Stanley
Morgan Stanley lowers targets for Gap, Macy's, and four other levered retailers
03/13/20 Deutsche Bank
Capri Holdings downgraded to Hold from Buy at Deutsche Bank
02/03/20 BMO Capital
Capri Holdings initiated with an Outperform at BMO Capital
WLL Whiting Petroleum
$0.38 /

-0.2933 (-43.87%)

03/31/20 Stifel
Whiting Petroleum downgraded to Sell from Hold at Stifel
03/25/20 JPMorgan
Whiting Petroleum downgraded to Underweight from Neutral at JPMorgan
03/24/20 Barclays
Whiting Petroleum downgraded to Underweight from Equal Weight at Barclays
03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
EBS Emergent BioSolutions
$54.04 /

-3.78 (-6.54%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
Hot Stocks
Emergent BioSolutions in pact with Novavax to manufacture NanoFlu » 16:11
03/31/20
03/31
16:11
03/31/20
16:11
EBS

Emergent BioSolutions

$57.36 /

+3 (+5.52%)

, NVAX

Novavax

$13.48 /

-0.83 (-5.80%)

Emergent BioSolutions …

Emergent BioSolutions announced an agreement with Novavax (NVAX) whereby Emergent will provide molecule-to-market contract development and manufacturing, CDMO, services to produce Novavax's NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant. Novavax recently announced that NanoFlu met all primary objectives in its Phase 3 clinical trial evaluating immunogenicity and safety in adults aged 65 and older. "Emergent is pleased to expand our collaboration with Novavax to include large-scale production of NanoFlu, their novel influenza vaccine," said Syed T. Husain, SVP and CDMO business unit head at Emergent BioSolutions. "Our flexible and integrated CDMO offerings allow us to work with expedited timelines, execute on simultaneous engagements, and serve varying needs and approaches of customers like Novavax. As a trusted partner, we are committed to supporting Novavax's goals to advance their influenza program while maintaining the option to allocate capacity for a potential scaled-up COVID-19 program." Under the terms of the agreement, Emergent will provide drug substance manufacturing services, including technology transfer and process validation and performance qualification to pave the way for commercial manufacturing. This work will be conducted at Emergent's Baltimore Bayview location, which is designated by the U.S. Department of Health and Human Services, HHS as a Center for Innovation in Advanced Development and Manufacturing, CIADM, and where the COVID-19 experimental vaccine candidate of Novavax is also being produced. The collaboration allows for flexibility to deploy capacity towards an expanded COVID-19 program.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$57.36 /

+3 (+5.52%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
11/22/19 Cantor Fitzgerald
Cantor reiterates Overweight on Emergent BioSolutions with $75 price target
NVAX Novavax
$13.48 /

-0.83 (-5.80%)

03/27/20 B. Riley FBR
Novavax price target raised to $20 from $15 at B. Riley FBR
03/25/20 Cantor Fitzgerald
Novavax price target raised to $23 from $16 at Cantor Fitzgerald
03/25/20 H.C. Wainwright
Novavax price target raised to $24 from $17 at H.C. Wainwright
03/24/20 Ladenburg
Novavax price target raised to $24 from $16 at Ladenburg

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.